Law360, New York (January 08, 2010, 4:18 PM ET) -- A federal appeals court won't budge on its finding that Cell Therapeutics Inc.’s settlement of a qui tam suit should not preclude CTI from seeking contractual indemnification from its reimbursement consultant, a predecessor of Lash Group Inc., for damages as part of the government’s investigation of its leukemia treatment Trisonex.
The U.S. Court of Appeals for the Ninth Circuit on Wednesday denied a petition for panel rehearing and rehearing en banc, requested by Lash, and said no further petitions would be entertained.
The Ninth Circuit revised...
9th Circ. Denies Rehearing In CTI Contract Suit
To view the full article, take a free trial now.
